Skip to main content

Table 2 Treatment profile

From: Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study

Variable Total (n = 38)
TACE method, n (%)
cTACE 20 (52.6%)
D-TACE 17 (44.7%)
Unknown 1 (2.6%)
TACE sessions, n (range) 3 (1, 13)
Regorafenib initial dosage, n (%)
20 mg/d 1 (2.6%)
80 mg/d 10 (26.3%)
120 mg/d 15 (39.5%)
160 mg/d 11 (28.9%)
Unknown 1 (2.6%)
Stopped regorafenib 15 (39.5%)
Reasons for stopping
Progression 9 (23.7%)
Intolerance 5 (13.2%)
Other 1 (2.6%)
  1. ECOG Eastern Cooperative Oncology Group